What does SAHA stand for?

Suberoylanilide Hydroxamic Acid (HDAC inhibitor)

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Summer's Almost Here Sydney Airport Hotel Iran Aircraft Industries (Persian) Sacramento Area Handball Association Social and Health Assessment South African History Archive (Braamfontein, South Africa) South African Hockey Association (field hockey) Southern Alleghenies Hardwood Association Stop Autoroute en Haute-Ariège (French: Stop Highway Haute-Ariège; Haute-Ariège, France) Student Advisory & Health Administration (Tufts University; Medford, MA)		Society of Architectural Historians, Australia and New Zealand Safety as High as Reasonably Achievable (nuclear safety principle) Social Aspects of HIV/AIDS Research Alliance Society for Scientific Advancement of Hills & Rural Areas South Asian Helpline and Referral Agency (Artesia, CA) Sensational Alex Harvey Band Southern Arizona Home Builders Association School of Arts, Histories and Cultures (University of Manchester; Manchester, England, UK) Société d'Angioédème Héréditaire du Canada South African High Commission (diplomatic mission)

Samples in periodicals archive:

Scientists at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, led by MSKCC president emeritus Paul Marks, have discovered that the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) causes cancer cells to stop growing and die.

Silent advances

and British colleagues added an HDAC inhibitor called suberoylanilide hydroxamic acid to the drinking water of young mice genetically engineered to make mutated huntingtin protein.

Drug limits disease effects in laboratory mice. (Huntington's Advance)

About ZOLINZA ZOLINZA, also known as vorinostat or suberoylanilide hydroxamic acid (SAHA), is Merck's investigational histone deacetylase (HDAC) inhibitor and part of a new class of anti-tumoragents under investigation for the treatment of solid tumors and cancers of the blood (lymphomas).

ZOLINZA(TM), Merck's Investigational Medicine for Advanced Cutaneous ...

Merck's Phase II cancer compound, suberoylanilide hydroxamic acid (SAHA) has the potential to provide important advances in the treatment of certain forms of cancer.

Merck Focused on Future Growth Prospects

Aton's lead product candidate, known as suberoylanilide hydroxamic acid (SAHA), has been studied in Phase I clinical trials in cancer patients and is currently in Phase II clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL).

Merck & Co., Inc. to Acquire Aton Pharma, Inc.; Acquisition Enhances ...